Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K4 | P45985 | 6/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | PDE1A | P54750 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.35 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.35 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25667804 | 0.84 | MAPK1 (0.32) | MAP2K4MAPK1MAPKAPK2MAPK6 | |
| SCHEMBL25696168 | 0.80 | MAP2K4 (0.33) | MAP2K4ADORA1PDE1APDE1BPDE3B | |
| SCHEMBL19104288 | 0.80 | MAP2K4 (0.35) | MAP2K4ADORA1PDE1APDE1BPDE3B | |
| SCHEMBL23916669 | 0.76 | MAP2K4 (0.30) | MAP2K4 | |
| SCHEMBL25667658 | 0.76 | MAPK1 (0.40) | MAP2K4MAPK1MAPKAPK2MAPK6MAPKAPK3 | |
| SCHEMBL18408664 | 0.75 | CYP1A2 (0.37) | MAP2K4PDE3BPDE3AMAPK1MAPKAPK2 | |
| SCHEMBL25668864 | 0.73 | LRRK2 (0.37) | MAP2K4MAPK1MAPKAPK2MAPK6 | |
| SCHEMBL25667774 | 0.72 | MAPK1 (0.33) | MAP2K4MAPK1MAPKAPK2MAPK6 | |
| SCHEMBL16646966 | 0.72 | MAPK1 (0.33) | MAP2K4MAPK1MAPKAPK2MAPK6 | |
| SCHEMBL23206119 | 0.72 | GAA (0.35) | MAP2K4MAPK1MAPKAPK2MAPK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328229-A2 | SUBSTITUTED HETEROCYCLIC FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | MAP2K4 327/4885ADORA1 1485/4885PDE1A 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.